IMUX
Price
$8.04Alerts
Change
+$0.08 (+1.01%)
Updated
Nov 10 closing price
Capitalization
105.74M
2 days until earnings call
Intraday BUY SELL Signals
PMCB
Price
$0.40Alerts
Change
-$0.01 (-2.44%)
Updated
Nov 10 closing price
Capitalization
3.86M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMUX vs PMCB

IMUX vs PMCB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMUX vs. PMCB commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Buy and PMCB is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMUX with price predictions
Nov 09, 2026

IMUX's RSI Indicator ascending out of oversold territory

The RSI Indicator for IMUX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 29 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IMUX as a result. In 77 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 212 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where IMUX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (3.498). P/E Ratio (-2.183) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PMCB with price predictions
Nov 09, 2026

PMCB's RSI Oscillator recovers from oversold territory

The RSI Oscillator for PMCB moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 26 of the 32 cases the stock moved higher. This puts the odds of a move higher at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where PMCB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PMCB as a result. In 92 of 121 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for PMCB just turned positive on November 03, 2026. Looking at past instances where PMCB's MACD turned positive, the stock continued to rise in 42 of 57 cases over the following month. The odds of a continued upward trend are 74%.

PMCB moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +22.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMCB advanced for three days, in 154 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

PMCB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PMCB entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.138) is normal, around the industry mean (3.498). P/E Ratio (-0.173) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PMCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMUX vs PMCB: Fundamental Ratings
IMUX
PMCB
OUTLOOK RATING
1..100
1936
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6382
P/E GROWTH RATING
1..100
1098
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUX's Valuation (31) in the Pharmaceuticals Major industry is in the same range as PMCB (43) in the null industry. This means that IMUX’s stock grew similarly to PMCB’s over the last 12 months.

IMUX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PMCB (100) in the null industry. This means that IMUX’s stock grew similarly to PMCB’s over the last 12 months.

PMCB's SMR Rating (98) in the null industry is in the same range as IMUX (99) in the Pharmaceuticals Major industry. This means that PMCB’s stock grew similarly to IMUX’s over the last 12 months.

IMUX's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as PMCB (82) in the null industry. This means that IMUX’s stock grew similarly to PMCB’s over the last 12 months.

IMUX's P/E Growth Rating (10) in the Pharmaceuticals Major industry is significantly better than the same rating for PMCB (98) in the null industry. This means that IMUX’s stock grew significantly faster than PMCB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUXPMCB
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 7 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (IMUX: $7.96 vs. PMCB: $0.41)
Brand notoriety: IMUX and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUX: 79% vs. PMCB: 76%
Market capitalization -- IMUX: $105.74M vs. PMCB: $3.86M
IMUX [@Biotechnology] is valued at $105.74M. PMCB’s [@Biotechnology] market capitalization is $3.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUX’s FA Score shows that 2 FA rating(s) are green while PMCB’s FA Score has 0 green FA rating(s).

  • IMUX’s FA Score: 2 green, 3 red.
  • PMCB’s FA Score: 0 green, 5 red.
According to our system of comparison, IMUX is a better buy in the long-term than PMCB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUX’s TA Score shows that 4 TA indicator(s) are bullish while PMCB’s TA Score has 6 bullish TA indicator(s).

  • IMUX’s TA Score: 4 bullish, 4 bearish.
  • PMCB’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PMCB is a better buy in the short-term than IMUX.

Price Growth

IMUX (@Biotechnology) experienced а +8.45% price change this week, while PMCB (@Biotechnology) price change was +31.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.45%. For the same industry, the average monthly price growth was -9.25%, and the average quarterly price growth was +81.75%.

Reported Earning Dates

IMUX is expected to report earnings on Nov 12, 2026.

PMCB is expected to report earnings on Dec 17, 2026.

Industries' Descriptions

@Biotechnology (+0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with WHWK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
+2.71%
WHWK - IMUX
38%
Loosely correlated
+2.88%
VYGR - IMUX
38%
Loosely correlated
+6.70%
EDIT - IMUX
36%
Loosely correlated
+7.00%
SGMT - IMUX
36%
Loosely correlated
+9.95%
CCCC - IMUX
36%
Loosely correlated
+1.61%
More

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and FATE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
+13.06%
FATE - PMCB
33%
Poorly correlated
+5.72%
SLDB - PMCB
32%
Poorly correlated
+6.53%
TOVX - PMCB
32%
Poorly correlated
-0.42%
CAPR - PMCB
31%
Poorly correlated
+9.44%
IMUX - PMCB
29%
Poorly correlated
+2.71%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ASTY1.680.37
+28.24%
Defiance Daily Target 2X Long ASTS ETF (ASTY)
QEW28.650.89
+3.22%
Invesco QQQ Equal Weight ETF (QEW)
KBA28.830.45
+1.59%
KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA)
PFFD17.100.19
+1.12%
Global X U.S. Preferred ETF (PFFD)
BSMR23.560.01
+0.04%
Invesco BulletShares 2027 Municipal Bond ETF (BSMR)